Medtronic Announces FDA Approval to Enroll First U.S. Renal Denervation Clinical Study

The FDA has approved an investigational device exemption allowing Medtronic to initiate Symplicity HTN-4, the first randomized trial to investigate renal denervation for the treatment of moderate uncontrolled hypertension in U.S. patients.
MarketWatch